Close Menu

NEW YORK (GenomeWeb News) – The US Food and Drug Administration said yesterday that it has granted BioMérieux's Vitek MS clinical microbiology mass spectrometry system 510(k) de novo clearance.

The system, which uses MALDI-TOF mass spec to identify disease-causing organisms including bacteria and yeast, is the first such platform cleared for clinical use in the US. The Vitek MS identifies microbes by matching the protein profiles of sample organisms generated via MALDI mass spec to profiles contained in a proprietary database.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.